Clinical trials
Phase 2 Shock, Septic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
95 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 2 |
| 2004 | 2 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 7 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 11 |
| 2019 | 10 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 7 |
| 2023 | 5 |
| 2024 | 5 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 49 |
| Unknown status | 20 |
| Terminated | 8 |
| Withdrawn | 7 |
| Recruiting | 6 |
| Not yet recruiting | 3 |
| Active, not recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dascena | 5 |
| University of Roma La Sapienza | 5 |
| AstraZeneca | 3 |
| Mahidol University | 3 |
| Mansoura University | 3 |
| Ottawa Hospital Research Institute | 3 |
| University of Manitoba | 3 |
| Ferring Pharmaceuticals | 2 |
| Inotrem | 2 |
| M.D. Anderson Cancer Center | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Shock, Septic | 95 |
| Sepsis | 52 |
| Shock | 6 |
| Systemic Inflammatory Response Syndrome | 6 |
| Infections | 5 |
| Disease | 4 |
| Acute Kidney Injury | 3 |
| Critical Illness | 3 |
| Inflammation | 3 |
| Multiple Organ Failure | 2 |
Trials
Showing 51 to 75 of 95. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.